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Exacerbation of sleep apnoea by frequent central events in
patients with the obstructive sleep apnoea syndrome at altitude: a
randomised trial
Abstract
BACKGROUND Many patients with the obstructive sleep apnoea syndrome (OSA) travel to the
mountains for recreational and professional activities while temporarily discontinuing continuous
positive airway pressure (CPAP) treatment. A study was undertaken to evaluate the hypothesis that
altitude would aggravate their hypoxaemia, sleep-related breathing disturbances and impair daytime
performance. METHODS Thirty-four patients with OSA of median age 62 years (IQR 57-65), median
apnoea/hypopnoea index (AHI) 47.5 events/h (IQR 32.4-72.8), residing at <600 m were enrolled. A
crossover trial randomised for the sequence of altitude exposure was carried out: patients spent 1 day in
Zurich (490 m) and 4 days in the Swiss Alps at 1860 m and 2590 m (2 days each) during which
continuous positive airway pressure was discontinued. Daily evaluations included polysomnography,
symptom questionnaires, physical examination and driving simulator tests. RESULTS
Polysomnography revealed median oxygen saturations at 490 m and in the first and second nights at
1860 and 2590 m, respectively, of 94%, 90%, 90%, 86% and 87% (p<0.01 between altitudes).
Corresponding median AHI were 47.5, 85.1, 74.6, 90.0 and 90.9 events/h (p<0.01 between altitudes)
with ratios of central to obstructive events of 0.1, 0.8, 1.0, 1.9 and 1.9 (p<0.01 between altitudes).
Tracking performance during simulated driving was significantly impaired at 2590 m compared with
490 m. Systolic blood pressure and cardiac arrhythmias were increased at altitude. CONCLUSIONS
Altitude exposure in untreated patients with OSA aggravates hypoxaemia, increases sleep-related
breathing disturbances due to frequent central apnoeas/hypopnoeas, impairs driving simulator
performance and induces cardiovascular stress. These findings have implications for counselling and
treating patients with OSA planning to travel to high altitude. ClinicalTrials.gov identifier
NCT00514826.
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ABSTRACT
Background Many patients with the obstructive sleep
apnoea syndrome (OSA) travel to the mountains for
recreational and professional activities while temporarily
discontinuing continuous positive airway pressure (CPAP)
treatment. A study was undertaken to evaluate the
hypothesis that altitude would aggravate their
hypoxaemia, sleep-related breathing disturbances and
impair daytime performance.
Methods Thirty-four patients with OSA of median age
62 years (IQR 57e65), median apnoea/hypopnoea index
(AHI) 47.5 events/h (IQR 32.4e72.8), residing at
<600 m were enrolled. A crossover trial randomised for
the sequence of altitude exposure was carried out:
patients spent 1 day in Zurich (490 m) and 4 days in the
Swiss Alps at 1860 m and 2590 m (2 days each) during
which continuous positive airway pressure was
discontinued. Daily evaluations included
polysomnography, symptom questionnaires, physical
examination and driving simulator tests.
Results Polysomnography revealed median oxygen
saturations at 490 m and in the first and second nights
at 1860 and 2590 m, respectively, of 94%, 90%, 90%,
86% and 87% (p<0.01 between altitudes).
Corresponding median AHI were 47.5, 85.1, 74.6, 90.0
and 90.9 events/h (p<0.01 between altitudes) with
ratios of central to obstructive events of 0.1, 0.8, 1.0, 1.9
and 1.9 (p<0.01 between altitudes). Tracking
performance during simulated driving was significantly
impaired at 2590 m compared with 490 m. Systolic
blood pressure and cardiac arrhythmias were increased
at altitude.
Conclusions Altitude exposure in untreated patients
with OSA aggravates hypoxaemia, increases sleep-
related breathing disturbances due to frequent central
apnoeas/hypopnoeas, impairs driving simulator
performance and induces cardiovascular stress. These
findings have implications for counselling and treating
patients with OSA planning to travel to high altitude.
ClinicalTrials.gov identifier NCT00514826.
INTRODUCTION
The obstructive sleep apnoea syndrome (OSA) is
caused by repetitive collapse of the upper airway
during sleep, provoking apnoeas/hypopnoeas asso-
ciated with oxygen desaturations and sleep
disruption.1 Excessive daytime sleepiness, loss of
concentration and other symptoms considerably
impair the quality of life of patients with OSA, and
they are at increased risk of causing traffic acci-
dents2 and suffering from cardiovascular disease.3
At least 5e10% of the adult population are affected
to some extent.4 Nocturnal application of contin-
uous positive airway pressure (CPAP) via a mask is
currently the most effective treatment. It improves
breathing disturbances, sleep quality and daytime
symptoms.
Worldwide, a large number of individuals residing
at low altitude travel to higher altitudes for work
and recreational activities. In various mountain
areas including the Alps, the Rocky Mountains and
the Andes, settlements are located at altitudes
between 1000 and 3000 m, and certain towns,
lodges and mountain huts are situated at even
higher elevations. High altitude periodic breathing
associated with sleep disturbance and altitude-
related illness such as acute mountain sickness and
high altitude cerebral and pulmonary oedema may
affect unacclimatised healthy lowlanders when
travelling to high altitudes.5 Whether altitude
exposure has similar or even more unfavorable
consequences in patients with OSA is largely
unknown although, because of the high prevalence
of the disorder, many are expected to travel to
altitude. Based on pathophysiological consider-
ations and uncontrolled observations in a small
number of patients, there have been concerns that
a stay at altitude might aggravate sleep-related
breathing disturbances in patients with OSA and
induce central apnoea,6 7 but more robust evidence
would be desirable as a basis for counselling and
treating patients with OSA travelling to altitude. A
randomised controlled trial was performed to
evaluate the hypothesis that exposure to moderate
altitude would aggravate nocturnal hypoxaemia,
sleep and breathing disturbances and impair
daytime performance in patients with OSA residing
at low altitude and discontinuing CPAP during
a 4-day stay at altitude.
METHODS
Patients
Patients with OSA on CPAP therapy were invited
to participate in the study by flyers distributed at
the University Hospital of Zurich and the Zurich
Lung League. Patients aged >20 years living at an
altitude below 600 m were considered for partici-
pation if a prior diagnosis of OSA was documented
by medical records and history confirming excessive
sleepiness and an apnoea/hypopnoea index (AHI)
>20/h before initiation of CPAP treatment. Study
inclusion further required >15 oxygen desatura-
tions/h (>3% dips) during an ambulatory pulse
oximetry (PULSOX 300i, Konica Minolta, Osaka,
Japan) performed during the last of four nights of
CPAP withdrawal that allowed sleep-disordered
breathing to return to near the untreated level.8 9
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Patients also had to have an AHI >10/h with predominant
obstructive apnoea/hypopnoea during polysomnography at low
altitude (Zurich, 490 m). The following conditions excluded
study admission: unstable cardiovascular disease, any lung
disease, internal medical, neurological or psychiatric disease
thought to interfere with sleep quality, chronic rhinitis, previous
upper airway surgery, use of medication that interferes with
ventilation or sleep (acetazolamide, benzodiazepines, opioids).
Protocol
A randomised controlled crossover trial was performed to eval-
uate the effects of altitude on untreated OSA. For logistic
reasons, during the study period from July to October 2007
a total number of 40 time slots were available that allowed 40
patients to be allocated to two different sequences of interven-
tions and evaluations (A and B) according to a balanced block
design. In order to control for a potential order effect, 20
sequence A (starting with low altitude studies and ending with
high altitude studies) and 20 sequence B (starting with high
altitude studies and ending with low altitude studies) were
available and allocated to time slots at random (figure 1). Details
of the sequences and the fact that selecting any particular time
slot determined the sequence were concealed from patients until
allocation was complete. Randomisation was achieved by letting
patients register for one of the available time slots according to
their preference (without being aware of the corresponding
sequence) until all slots were filled.
Patients discontinued CPAP for a total of eight nights. Days
1e3 were spent at home (<600 m) while the effect of CPAP was
washed out. Patients assigned to sequence A spent day 4 in
Zurich (490 m, 1608 ft, barometric pressure (PB) 717 Torr), days
5e6 in Davos Schatzalp (1860 m, 6103 ft, PB 607 Torr) and days
7e8 in Davos Jakobshorn (2590 m, 8498 ft, PB 554 Torr).
Patients assigned to sequence B spent days 1e3 at home, days
4e5 in Davos Jakobshorn, days 6e7 in Davos Schatzalp and day
8 in Zurich (figure 1). Transfers between Zurich and Davos,
a village in the Swiss Alps, were by a 2.5 h train ride and
between Davos train station and Schatzalp and Jakobshorn,
respectively, by cable car. Patients spent nights in sleep labora-
tories at the study locations.
Outcomes
Examinations after waking up in the morning included pulse
oximetry, body weight and sphygmomanometric blood pressure.
Acute mountain sickness was assessed by the Lake Louise
protocol10 which evaluates headaches, gastrointestinal upset,
fatigue/weakness, dizziness/light-headedness, difficulty sleeping
and peripheral oedema, tachypnoea, altered mental status and
ataxia. The score ranges from 0 to 24 points with increasing
severity of acute mountain sickness. Sleepiness was assessed by
the Karolinska Sleepiness Scale11 ranging from 1 (very awake) to
9 (very tired). During a 30 min test drive with the Divided
Attention Driving Simulator, the tracking error (deviation from
centre line) and reaction time were recorded.12
Polysomnography was performed from approximately 22:00 h
to 06:00 h according to standard techniques13 (Alice5, Respir-
onics AG, Zofingen, Switzerland). Derivations included electro-
encephalogram (EEG) and electro-oculogram (EOG) leads,
submental and bilateral anterior tibial electgromyogram (EMG),
pulse oximetry, calibrated respiratory inductive plethysmog-
raphy,14 nasal prong pressure recordings,15 bilateral diaphrag-
matic surface EMG,16 end-tidal and transcutaneous carbon
dioxide tension (Ptcco2).17 18 Sleep stages and arousals were
scored.19 20 Apnoea/hypopnoea was defined as a reduction in the
inductive plethysmographic sum signal or the nasal pressure
swings to<50% of the preceding 2 min baseline during$10 s.15 21
Transient reductions in breathing amplitude to<50% baseline for
5e10 s were also scored as apnoeas/hypopnoeas if they occurred
as part of a periodic breathing pattern with hyperventilation
alternating with central apnoeas/hypopnoeas for at least three
consecutive cycles.22 Obstructive apnoeas/hypopnoeas were
identified by rib cage and abdominal asynchrony and persistent or
increasing diaphragmatic EMG activity (figure 2). Central
apnoeas/hypopnoeas were identified by absent rib cage-abdom-
inal asynchrony, no signs of inspiratory flow limitation (no flat-
tening of nasal pressure contour) and reduced or absent
diaphragmatic EMG activity. The AHI and the oxygen desatura-
tion index (>3%dips)were computed as the number of events per
hour of sleep. The sleep study analysts were blinded to the clinical
data.
Data analysis
Data are summarised as medians and interquartile ranges. The
effects of altitude and time at any altitude were evaluated by
Friedman ANOVA followed by Wilcoxon matched pairs tests if
ANOVA indicated a significant overall effect. To test the
hypothesis that outcomes at altitude (ie, at 1860 m and 2590 m,
days 1 and 2, respectively) differed from those at 490 m, we
planned to perform four comparisons. To account for this, we
assumed statistical significance at p<0.01 (ie, we performed
a Bonferroni correction by factor 5 rather than 4 to be conserva-
tive). In additional exploratory comparisons between data from
altitudes 1860 m and 2590 m, we adjusted the statistical
Figure 1 Study flow chart. AHI, apnoea/hypopnoea index; CPAP,
continuous positive airway pressure.
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significance of the p value from 0.05 by a factor of 10 to 0.005 (10
possible comparisons between data from all three altitudes and
days 1 and 2). The primary outcomes were oxygen saturation and
AHI, and secondary outcomes were sleep quality and vigilance,
symptoms and physical findings. Clinically relevant differences
were assumed to be 2% (SD 2%) for oxygen saturation and 10/h
(SD 15/h) for the AHI. Power calculation indicated a minimal
sample size of 29 to detect clinically relevant differences in
primary outcomes with a power of 80% (a¼0.01). To account for
potential drop-outs, our aim was to recruit 40 patients.
RESULTS
Patients
Figure 1 illustrates the patient flow. Of 68 patients who applied
to participate in the study, 40 met the inclusion criteria and were
randomised. One patient withdrew after one night at Jakobs-
horn because of lack of motivation. Data from five patients had
to be excluded according to predefined criteria because baseline
polysomnography at low altitude (Zurich) revealed an obstruc-
tive AHI <10/h in two, predominant central apnoeas/hypo-
pnoeas in two and alveolar hypoventilation in one. Data from 34
patients (32 men, 2 women) were available for analysis. Median
(IQR) age was 62 (57e65) years and body mass index was 33.7
(27.3e38.1) kg/m2. Patients had been on CPAP treatment for 41
(20e56) months. Comorbidities included arterial hypertension
in 68% and diabetes mellitus in 15% of subjects; 38% were
receiving ACE inhibitors/angiotensin II antagonists, 35%
diuretics, 24% b blockers and 18% calcium channel blockers. No
serious adverse events requiring medical treatment occurred.
Sleep studies
The sleep study results are summarised in table 1 and data on
nocturnal ventilation, oxygen saturation and heart rate are
shown in table 2. A representative recording is shown in figure 2.
A comparison of the data from subjects undergoing sequences A
and B did not reveal significant differences in oxygen saturation,
AHI, percentage slow wave sleep and sleep efficiency, so the data
from the two groups are presented together. Compared with
values recorded at 490 m, oxygen saturation was significantly
reduced at 1860 m and even more so at 2590 m, particularly
during REM sleep. Transcutaneous PCO2 was highest at 490 m
during REM sleep and lowest at 2590 m during NREM sleep.
Studies at 490 m revealed severe OSA and only occasional
central apnoeas/hypopnoeas according to inclusion criteria. On
the first and second day at 1860 and 2590 m, respectively, the
AHI increased significantly to medians of 147%, 141% and
166%, 167% of the 490 m baseline value. This was related to the
emergence of frequent central apnoeas/hypopnoeas during
NREM sleep while obstructive apnoeas/hypopnoeas persisted
(figure 3). Sleep quality worsened significantly at altitude as
reflected in an increased arousal index, reduced sleep efficiency
and slow wave sleep (NREM stages III and IV) at 2590 m. The
number of arousals was significantly correlated with the AHI at
all altitudes (at 490 m: Spearman R¼0.77; 1860 m, day 1:
R¼0.70; 1860 m, day 2: R¼0.77; 2590 m, day 1: R¼0.68; 2590 m,
day 2: R¼0.77; p<0.01 in all instances). Compared with 490 m,
the heart rate and the number of premature beats were signifi-
cantly increased at altitude.
Comparisons of sleep studies on the first versus the second
night at corresponding altitude revealed no effect of acclimati-
sation on oxygen saturation and transcutaneous PCO2.
Symptoms and daytime findings
In the morning the Karolinski Sleepiness Scale indicated that
patients felt moderately sleepy (table 3). They reported
moderate symptoms of acute mountain sickness at altitude but
the Lake Louise score was also increased at 490 m. None of the
patients had symptoms or signs of high altitude pulmonary
oedema. There was an increase in weight at 2590 m compared
with 490 and 1860 m, and this was associated with ankle
oedema. Systolic blood pressure was increased at 1860 m and
2590 m above values at 490 m (table 3). In two patients anti-
hypertensive medication needed to be adapted at 2590 m
because of an excessive rise in blood pressure. Driving simulator
tests revealed significantly increased tracking errors at 2590 m
compared with the lower altitudes (figure 4).
DISCUSSION
We performed a randomised controlled crossover trial in patients
with moderate to severe OSA during temporary CPAP discontin-
uation to evaluate the effects of a 4-day stay atmoderate altitudes
Figure 2 Polysomnographic recordings obtained in a representative
patient during NREM sleep stage II at Zurich (490 m) and at Davos
Jakobshorn (2590 m). At 490 m, intermittent absence of nasal pressure
swings with paradoxical rib cage and abdominal excursions and
persistent diaphragmatic EMG activity during events indicate that
apnoeas are obstructive. At 2590 m, the intermittent absence of rib cage
abdominal motion and diaphragmatic EMG activity indicates that
apnoeas are central. Traces are a central EEG derivation (C3A2), left and
right EOG (LEOG, REOG), submental EMG, nasal pressure swings (Pnas),
inductive plethysmographic sum, rib cage and abdominal volume curves,
left and right diaphragmatic EMG (EMGdiaL, EMGdiaR), oxygen
saturation by pulse oximetry (SpO2) and heart rate (HR).
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(1860 m and 2590 m) on sleep, breathing and daytime perfor-
mance. The main findings were a progressive reduction in
nocturnal oxygen saturation associated with hyperventilation
and a major increase in the AHI, particularly at the highest alti-
tude, due to frequent central apnoeas/hypopnoeas while
obstructive events persisted. Correspondingly, sleep quality and
driving simulator performance were impaired at altitude. Further
consequences of altitude exposurewere an increased prevalence of
nocturnal cardiac arrhythmias, a significant rise in heart rate and
in systolic blood pressure and a weight gain with peripheral
oedema.We conclude that a stay atmoderate altitude in untreated
patients with OSA is associated with unfavorable health effects.
In healthy subjects, hypobaric hypoxia at altitudes >2000 m
induces periodic breathing with central apnoea/hypopnoea.23e25
Breathing instability is related to hypoxic stimulation of ventila-
tion resulting in a reduced CO2 reservedthat is, an eupnoeic PCO2
close to the apnoea threshold promoting apnoea at a minor rise in
ventilation because enhanced chemosensitivity causes a ventila-
tory overshoot.26 Data on breathing patterns and sleep in patients
with OSA at altitude are scant. During exposure to a simulated
altitude of 2750 m (FIO2 16.05% at 610 m, PB 700 mm Hg), five
patients with OSA had an increase in central apnoeas and
a reduction in obstructive apnoeas compared with studies in
normoxia at sea level.6 In 11 patients with OSA undergoing
repeated sleep studies at an altitude>2400 m, at 1370 mand at sea
level (fivepatients), theAHIdecreasedwithdescent in altitudedue
to a reduction in central apnoeas.7 Our randomised trial corrobo-
rates and extends these observational studies by confirming
a dose-response relationship between progressive hypoxia at
increasing altitude, decreasing transcutaneous PCO2 reflecting
more pronounced hyperventilation and emergence of frequent
central apnoeas/hypopnoeas. The number of events scored as
central might have been even higher if we had not applied strin-
gent criteria requiring absence of signs of inspiratory flow limita-
tion, perfect synchronisation of rib cage-abdominal motion
recorded by calibrated inductive plethysmography and a reduced
or absent diaphragmatic surface EMG activity. This conservative
definition excluded central and mixed events with partial upper
airway occlusion. The increase in central apnoea index at altitude
occurred predominantly during NREM sleep but rarely during
REMsleep (figure 3). Thiswas consistentwith a greater increase in
hypoxic and hypercapnic ventilatory drive in NREM sleep
comparedwithREMsleep at altitude25 and awidenedCO2 reserve
and/or absence of a post-hyperventilation-induced apnoeic
threshold in REM sleep.27
In our study there was no significant change in the obstruc-
tive AHI at altitude (table 2). Presumably, factors contributing
to upper airway patency during hypoxia such as chemical
stimulation of dilator muscles were offset by factors promoting
airway collapse such as stimulation of ventilatory pump muscles
that increase the upper airway transmural pressure gradient
during vigorous inspiratory efforts.28 29 A shorter duration of
obstructive apnoea/hypopnoea at altitude (table 2) is consistent
with a lower arousal threshold and/or a lower recruitment
Table 1 Sleep studies (n¼32)
Zurich 490 m Davos Schatzalp 1860 m Davos Jakobshorn 2590 m
1st day 1st day 2nd day 1st day 2nd day
Total sleep time (min) 369 (345e388) 423* (389e467) 427* (405e458) 391z (303e457) 401yz (300e423)
Sleep efficiency (%) 86 (80e89) 82 (76e87) 79* (72e88) 78* (61e84) 71*yz (61e84)
NREM 1+2 (%) 74 (61e81) 74 (61e85) 74 (63e81) 82*yz (74e94) 81*z (69e93)
NREM 3+4 (%) 14 (8e22) 12 (4e19) 14 (8e17) 6*yz (0e12) 9*z (2e16)
REM (%) 13 (9e18) 13 (10e18) 13 (9e20) 10 yz (4e16) 10 (7e15)
Arousal index (1/h) 35.5 (25.1e43.2) 41.8* (33.5e61.1) 45.5* (29.9e56.7) 51.3* (37.6e65.5) 49.3* (34.4e65.7)
Values are median (IQR).
*p<0.01 vs 490 m.
yp<0.005 vs 1860 m, day 1.
zp<0.005 vs 1860 m, day 2.
Table 2 Nocturnal ventilation, oxygen saturation and heart rate (n¼34)
Zurich 490 m Davos Schatzalp 1860 m Davos Jakobshorn 2590 m
1st day 1st day 2nd day 1st day 2nd day
SpO2, entire night (%) 94 (93e95) 90* (88e91) 90* (88e91) 86*yz (84e89) 87*yz (84e89)
SpO2 during REM (%) 94x (93e95) 89*x (88e91) 90*x (88e91) 85*yzx (83e89) 86*yzx (84e89)
SpO2 during REM (%) 94 (90e95) 87* (84e91) 88* (85e91) 83*yz (78e88) 84*yz (81e87)
PtcCO2, entire night (mm Hg) 49 (44e50) 39* (36e41) 39* (37e41) 37* (33e42) 37*yz (33e39)
PtcCO2 during NREM (mm Hg) 49 (46e50) 40*x (37e44) 39*x (36e42) 38* (35e42) 39* (34e40)
PtcCO2 during REM (mm Hg) 51 (48e51) 41* (37e44) 43* (37e44) 40* (36e42) 39* (34e42)
Oxygen desaturation index (1/h) 37.3 (14.6e52.7) 67.6* (37.6e88.2) 57.4* (32.1e86.1) 80.6*yz (52.4e103.4) 71.5*yz (43.4e98.6)
Total AHI (events/h) 51.2 (31.7e74.4) 85.1* (53.9e94.3) 68.5* (51.3e95.7) 90.0*yz (64.2e103.2) 88.6*z (62.4e108.4)
Obstructive AHI (events/h) 39.4 (24.1e65.8) 32.1 (21.3e71.8) 33.0 (15.3e60.0) 32.0 (3.3e54.6) 25.2 (6.5e58.8)
Central AHI (events/h) 2.4 (0.4e8.8) 25.4* (17.0e55.9) 32.7* (14.2e43.7) 51.3*yz (32.8e75.5) 49.4*z (22.6e57.8)
Obstructive apnoea duration (s) 21.0 (16.4e24.9) 22.8 (17.7e26.6) 22.6 (18.5e27.8) 18.8z (13.3e22.8) 18.5z (15.4e24.1)
Central apnoea duration (s) 11.6 (8.9e18.2) 15.5* (13.2e19.3) 15.1 (12.7e19.4) 14.2y (12.5e16.7) 15.3 (12.2e18.3)
Heart rate (1/min) 57.2 (54.7e61.8) 61.1* (57.2e66.4) 61.5* (57.4e69.2) 66.5* (58.4e72.0) 62.6* (57.7e68.8)
Premature beats, entire night (1/h) 3.2 (0.6e11.2) 6.7 (1.2e33.6) 9.8* (3.0e31.0) 7.2 (2.2e29.6) 6.1 (1.2e30.4)
Values are median (IQR).
*p<0.01 vs 490 m.
yp<0.005 vs 1860 m, day 1.
zp<0.005 vs 1860 m, day 2.
xp<0.005 vs REM.
AHI, apnoea/hypopnoea index; PtcCO2, transcutaneous carbon dioxide tension; SpO2, oxygen saturation.
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threshold of upper airway dilator muscles in hypoxia compared
with normoxia.29
Sleep fragmentation and a reduced amount of slow wave sleep
have been reported previously in healthy subjects at
altitude.30e32 Correspondingly, we observed that sleep quality in
patients with OSA was impaired at altitude, as reflected in
a reduction in sleep efficiency and slow wave sleep and frequent
arousals (table 1). Correlation analysis indicated that 46e59% of
the variation in the arousal index was explained by the AHI,
suggesting a significant contribution of breathing disturbances
to sleep fragmentation although other factors might addition-
ally have impaired sleep quality in hypoxia.32 In five patients
with OSA studied at a simulated altitude of 2750 m (isobaric
hypoxia),6 no significant changes in sleep stages compared with
sea level studies were observed, possibly related to the small
sample size.
Questionnaire evaluation indicated that patients perceived
moderate headache, poor sleep quality and sleepiness even at
low altitude (table 3), which was probably due to CPAP with-
drawal. There was no clear further increase in these symptoms
at altitude (table 3). We cannot exclude the possibility that the
positive attitude towards a stay at altitude may have influenced
the perception of altitude-related symptoms in the study
participants. However, objective testing during a simulated car
drive indicated reduced psychomotor vigilance at 2590 m (table
3), highlighting the potential clinical relevance of exposure to
hypoxia in patients with OSA who already have cognitive
dysfunction in normoxia.12
OSA is associated with cardiac arrhythmia and systemic
hypertension at low altitude.3 In this study, patients had
a higher prevalence of nocturnal premature beats and a rise in
heart rate and systolic blood pressure at altitude (tables 2 and 3),
suggesting an additional cardiovascular effect of sustained
hypoxia and of the more pronounced breathing disturbances at
altitude, possibly related to sympathetic activation and para-
sympathetic withdrawal.33 34 The weight gain we observed in
association with the development of peripheral oedema (table 3)
is consistent with water retention, possibly mediated by
sympathetic overstimulation, rise in systemic and pulmonary
artery pressure and activation of the renin-angiotensin-aldoste-
rone system in patients with OSA with symptoms of acute
mountain sickness.35
In conclusion, this randomised crossover trial in patients with
OSA indicates that hypoxia, breathing and sleep disturbances
are more severe at altitude and are associated with signs of
cardiovascular stress and impaired driving simulator perfor-
mance. The results caution against altitude exposure of
untreated patients with OSA, and may help in the design of
Figure 3 Sleep-related breathing disturbances at 490 m and in the first
and second night at 1680 m and 2590 m, respectively. The bars and
horizontal lines represent median values and quartile ranges of
obstructive and central apnoea/hypopnoea indices at the different
locations. The upper panel represents events during NREM sleep and the
lower panel corresponding values during REM sleep. At higher altitudes,
the total apnoea/hypopnoea index increased significantly, related to the
emergence of central apnoea/hypopnoea during NREM sleep. *p<0.01
vs 490 m; **p<0.01 vs 490 m and vs 1860 m.
Table 3 Daytime evaluation
Zurich 490 m Davos Schatzalp 1860 m Davos Jakobshorn 2590 m
1st day 2nd day 1st day 2nd day
SpO2 (%) 95 (94e96) 93* (92e94) 94* (93e94) 91* (90e93) 92* (91e93)
Weight (kg) 98.8 (82.7e110.6) 98.0* (83.5e109) 98.5* (84e108) 99.0*yz (85.0e112.0) 100.0*yz (84e110)
Heart rate (1/min) 61 (57e66) 72* (66e77) 73* (69e77) 74* (64e80) 74* (64e78)
Systolic blood pressure (mm Hg) 130 (120e140) 143* (135e156) 145* (132e152) 144* (132e160) 144* (130e162)
Diastolic blood pressure (mm Hg) 85 (80e90) 86 (80e92) 86 (80e95) 85 (81e90) 90 (81e97)
Peripheral oedemax 0 (0e0) 0* (0e2) 0* (2e2) 0* (0e2) 0* (0e2)
Driving simulator reaction time (s) 3.4 (2.3e10.0) 3.1 (2.5e10.0) 2.9 (2.3e4.3) 10.0 (2.7e10.0) 10.0z (3.0e10.0)
Driving simulator tracking error 0.38 (0.32e0.55) 0.42 (0.34e0.55) 0.40 (0.30e0.47) 0.70*yz (0.51e0.90) 0.67*yz (0.49e0.89)
Lake Louise acute mountain sickness
score
2.5 (2.0e4.0) 3.0 (2.0e4.0) 2.0 (1.0e3.0) 4.0z (3.0e5.0) 3.0z (2.0e5.0)
Difficulty sleepingx 1 (1e2) 1 (1e1) 1y (0e1) 1.5z (1e2) 1 (1e2)
Karolinksa sleepiness score 4 (3e6) 3* (3e4) 3* (2e3) 3 (3e4) 3 (2e3)
Data were obtained in the morning after sleep studies. Values are median (IQR).
*p<0.01 vs 490 m.
yp<0.005 vs 1860 m, day 1.
zp<0.005 vs 1860 m, day 2.
xPeripheral oedema was rated as part of the Lake Louise acute mountain sickness protocol with 0 (absent), 1 (at one location) or 2 points (at two or more locations). Difficulty sleeping was
also rated within the Lake Louise protocol with 0 (slept as usual) to 3 points (could not sleep at all).
SpO2, oxygen saturation.
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further studies evaluating the effectiveness of CPAP and other
treatment modalities that might improve subjective well-being
and reduce the potential risk of traffic accidents and cardiovas-
cular complications in patients with OSA at altitude.
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Lung alert
Newly identified genetic determinants of lung function
It is well established that pulmonary function is in part genetically determined. These authors
report a meta-analysis of genome-wide association study (GWAS) results from 20 288
participants and follow-up analyses in 54 276 participants, identifying five novel genome-wide
significant loci for pulmonary function. A companion manuscript from the CHARGE
Consortium, which reports a GWAS of lung function in 20 890 participants, also identifies
significant associations at three of these sites. These loci were not specific to smokers, genetic
factors that influence smoking behaviour or adjustments for smoking exposure. The most
probable candidate genes in the regions identified seem to be involved in developmental
pathways important for lung growth or tissue remodelling.
While the authors admit that these determinants have been incompletely adjusted for
height and were based on cross-sectional measures of lung function, these findings are
important for two reasons. First, previous studies in chronic obstructive pulmonary disease
(COPD) have reported changes at similar loci, thus raising the possibility that the
development of COPD may be predetermined during lung development and further
influenced by cigarette smoke exposure. However, it also raises the possibility that the
move to define the diagnosis of COPD by abnormal lung function has led to the identification
of confounding loci that are simply determinants of lung development rather than disease
specific. Mechanistic and pathogenetic models are required to help determine which is the
more accurate. Secondly, the identification of multiple loci involved in early lung development
allows for a more targeted determination of the mechanisms by which the airways develop
and respond to external insult. Detailed longitudinal studies will be required to define and
address these issues.
As always with genome studies, more questions are generated than answered, but these
papers provide strong evidence for newly identified genetic loci that act as important
determinants of pulmonary function.
< Repapi E, Sayers I, Wain LV, et al. Genome-wide association study identifies five loci associated with lung function. Nat Genet
2010;42:36e44.
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